Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Azvudine
COVID-19
Nirmatrelvir/ritonavir
Older adults
Treatment effect
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
12
07
2023
accepted:
21
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients. This study explored the effectiveness and safety of azvudine in older adults with mild or moderate COVID-19. This retrospective cohort study included patients aged ≥80 diagnosed with COVID-19 at the Central Hospital of Shaoyang between October and November 2022. According to the therapies they received, the eligible patients were divided into the azvudine, nirmatrelvir/ritonavir, and standard-of-care (SOC) groups. The outcomes were the proportion of patients progressing to severe COVID-19, time to nucleic acid negative conversion (NANC), and the 5-, 7-, 10-, and 14-day NANC rates from admission. The study included 55 patients treated with azvudine (n = 14), nirmatrelvir/ritonavir (n = 18), and SOC (n = 23). The median time from symptom onset to NANC of the azvudine, nirmatrelvir/ritonavir, and SOC groups was 14 (range, 6-25), 15 (range, 11-24), and 19 (range, 18-23) days, respectively. The median time from treatment initiation to NANC of the azvudine and nirmatrelvir/ritonavir groups was 8 (range, 4-20) and 9 (range, 5-16) days, respectively. The median length of hospital stay in the three groups was 10.5 (range, 5-23), 13.5 (range, 10-21), and 17 (range, 10-23) days, respectively. No treatment-related adverse events or serious adverse events were reported. Azvudine showed satisfactory effectiveness and acceptable safety in older adults with mild or moderate COVID-19. Therefore, azvudine could be a treatment option for this special patient population.
Sections du résumé
BACKGROUND
BACKGROUND
Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients. This study explored the effectiveness and safety of azvudine in older adults with mild or moderate COVID-19.
METHODS
METHODS
This retrospective cohort study included patients aged ≥80 diagnosed with COVID-19 at the Central Hospital of Shaoyang between October and November 2022. According to the therapies they received, the eligible patients were divided into the azvudine, nirmatrelvir/ritonavir, and standard-of-care (SOC) groups. The outcomes were the proportion of patients progressing to severe COVID-19, time to nucleic acid negative conversion (NANC), and the 5-, 7-, 10-, and 14-day NANC rates from admission.
RESULTS
RESULTS
The study included 55 patients treated with azvudine (n = 14), nirmatrelvir/ritonavir (n = 18), and SOC (n = 23). The median time from symptom onset to NANC of the azvudine, nirmatrelvir/ritonavir, and SOC groups was 14 (range, 6-25), 15 (range, 11-24), and 19 (range, 18-23) days, respectively. The median time from treatment initiation to NANC of the azvudine and nirmatrelvir/ritonavir groups was 8 (range, 4-20) and 9 (range, 5-16) days, respectively. The median length of hospital stay in the three groups was 10.5 (range, 5-23), 13.5 (range, 10-21), and 17 (range, 10-23) days, respectively. No treatment-related adverse events or serious adverse events were reported.
CONCLUSION
CONCLUSIONS
Azvudine showed satisfactory effectiveness and acceptable safety in older adults with mild or moderate COVID-19. Therefore, azvudine could be a treatment option for this special patient population.
Identifiants
pubmed: 38177982
doi: 10.1186/s12879-023-08944-z
pii: 10.1186/s12879-023-08944-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Informations de copyright
© 2024. The Author(s).
Références
World Health Organization: Weekly epidemiological update on COVID-19 - 18 May 2023. Edition 143. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19%2D%2D-18-may-2023 . Accessed May 22, 2023. Geneva: World Health Organization; 2023.
El-Sadr WM, Vasan A, El-Mohandes A. Facing the new Covid-19 reality. N Engl J Med. 2023;388:385–7.
pubmed: 36724378
doi: 10.1056/NEJMp2213920
Hammad HM, Nauman HMF, Abbas F, Jawad R, Farhad W, Shahid M, et al. Impacts of COVID-19 pandemic on environment, society, and food security. Environ Sci Pollut Res Int. 2023;30:99261-72.
Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361–79.
pubmed: 37020110
doi: 10.1038/s41579-023-00878-2
Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286.e278.
pubmed: 36580913
pmcid: 9747694
doi: 10.1016/j.cell.2022.12.018
World Health Organization. Clinical management of COVID-19: living guideline. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.1 . Accessed 22 May 2023
Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, et al. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep. 2022;74:1120–48.
pubmed: 36214969
pmcid: 9549062
doi: 10.1007/s43440-022-00425-5
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43.
pubmed: 32167524
doi: 10.1001/jamainternmed.2020.0994
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
pubmed: 32171076
pmcid: 7270627
doi: 10.1016/S0140-6736(20)30566-3
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–71.
pubmed: 32201335
pmcid: 7198856
doi: 10.1016/j.jacc.2020.03.031
Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52:1193–4.
pubmed: 32222883
pmcid: 7103107
doi: 10.1007/s11255-020-02451-9
Ge J, Pletcher MJ, Lai JC, Consortium NC. Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a national COVID cohort collaborative study. Gastroenterology. 2021;161:1487–1501.e1485.
doi: 10.1053/j.gastro.2021.07.010
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36.
pubmed: 33146552
pmcid: 7781116
doi: 10.1164/rccm.202009-3533SO
Lebrasseur A, Fortin-Bedard N, Lettre J, Raymond E, Bussieres EL, Lapierre N, et al. Impact of the COVID-19 pandemic on older adults: rapid review. JMIR Aging. 2021;4:e26474.
pubmed: 33720839
pmcid: 8043147
doi: 10.2196/26474
Zhou Z, Zhang M, Wang Y, Zheng F, Huang Y, Huang K, et al. Clinical characteristics of older and younger patients infected with SARS-CoV-2. Aging (Albany NY). 2020;12:11296–305.
pubmed: 32575073
doi: 10.18632/aging.103535
Lamontagne F, Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. Bmj. 2020;370:m3379.
pubmed: 32887691
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–408.
pubmed: 35172054
doi: 10.1056/NEJMoa2118542
Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;381:e073312.
pubmed: 37041016
doi: 10.1136/bmj-2022-073312
Zareifopoulos N, Lagadinou M, Karela A, Kyriakopoulou O, Velissaris D. Neuropsychiatric Effects of Antiviral Drugs. Cureus. 2020;12:e9536.
pubmed: 32905132
pmcid: 7465925
Kanai O, Fujita K, Nanba K, Esaka N, Hata H, Seta K, et al. Safety of Remdesivir for patients 80 years of age or older with coronavirus disease 2019 (COVID-19). Drugs Aging. 2021;38:1067–74.
pubmed: 34859387
pmcid: 8638643
doi: 10.1007/s40266-021-00908-9
Zhang J-L, Li Y-H, Wang L-L, Liu H-Q, Lu S-Y, Liu Y, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6:414.
pubmed: 34873151
pmcid: 8646019
doi: 10.1038/s41392-021-00835-6
Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, et al. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. Adv Sci (Weinh). 2020;7:e2001435.
pubmed: 35403380
doi: 10.1002/advs.202001435
da Silva RM, Gebe Abreu Cabral P, de Souza SB, Arruda RF, Cabral SPF, de Assis A, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med (Lausanne). 2023;10:1143485.
pubmed: 37007788
doi: 10.3389/fmed.2023.1143485
Kale A, Shelke V, Dagar N, Anders HJ, Gaikwad AB. How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front Pharmacol. 2023;14:1053814.
pubmed: 36843922
pmcid: 9947246
doi: 10.3389/fphar.2023.1053814
Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 2020;97:1297–8.
pubmed: 32317113
pmcid: 7271263
doi: 10.1016/j.kint.2020.03.015
Sun Y, Jin L, Dian Y, Shem M, Zeng F, Chen X, et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. eClinicalMedicine. 2023;59:101981.
pubmed: 37193346
pmcid: 10167478
doi: 10.1016/j.eclinm.2023.101981
Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv; 2021.
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22:1293–302.
pubmed: 35753318
pmcid: 9225255
doi: 10.1016/S1473-3099(22)00320-6
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J. Consortium C-GU, Peacock SJ, Barclay WS, de Silva TI, towers GJ, Robertson DL: SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–77.
pubmed: 36653446
pmcid: 9847462
Rouzine IM, Rozhnova G. Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. Commun Med (Lond). 2023;3:86.
pubmed: 37336956
doi: 10.1038/s43856-023-00320-x
Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15:228–40.
pubmed: 35042059
pmcid: 8730674
doi: 10.1016/j.jiph.2021.12.014
Monto AS. The future of SARS-CoV-2 vaccination - lessons from influenza. N Engl J Med. 2021;385:1825–7.
pubmed: 34739199
doi: 10.1056/NEJMp2113403
Wheatley AK, Fox A, Tan HX, Juno JA, Davenport MP, Subbarao K, et al. Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 2021;42:956–9.
pubmed: 34580004
pmcid: 8440232
doi: 10.1016/j.it.2021.09.001
Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, et al. 2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem. 2008;283:2167–75.
pubmed: 18003608
doi: 10.1074/jbc.M708929200
Xu N, Yang J, Zheng B, Zhang Y, Cao Y, Huan C, et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J Virol. 2020;94:10–128.
doi: 10.1128/JVI.00204-20
Wang RR, Yang QH, Luo RH, Peng YM, Dai SX, Zhang XJ, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014;9:e105617.
pubmed: 25144636
pmcid: 4140803
doi: 10.1371/journal.pone.0105617
Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol. 2007;81:7238–48.
pubmed: 17428847
pmcid: 1933265
doi: 10.1128/JVI.02584-06
Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023;95:e28756.
pubmed: 37185838
doi: 10.1002/jmv.28756
Chen W, Xu H, Hong L, Yang R, Peng C, Wang G, et al. Oral Azvudine (FNC) tablets in patients infected with SARS-CoV-2 omicron variant: a retrospective cohort study. medRxiv. 2023; 2023.01.05.23284180. https://www.medrxiv.org/content/10.1101/2023.01.05.23284180v1.article-info .
Chen Z, Tian F. Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis. Heliyon. 2023;9:e20153.
pubmed: 37809649
pmcid: 10559905
doi: 10.1016/j.heliyon.2023.e20153
Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Inf Secur. 2023;87:e24–7.
McGovern J, Al-Azzawi Y, Kemp O, Moffitt P, Richards C, Dolan RD, et al. The relationship between frailty, nutritional status, co-morbidity, CT-body composition and systemic inflammation in patients with COVID-19. J Transl Med. 2022;20:98.
pubmed: 35189900
pmcid: 8860274
doi: 10.1186/s12967-022-03300-2
Hussien H, Nastasa A, Apetrii M, Nistor I, Petrovic M, Covic A. Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones. BMC Geriatr. 2021;21:389.
pubmed: 34176479
pmcid: 8236311
doi: 10.1186/s12877-021-02316-5
Zhang L, Zhang S, Han J, Yi Y, Zhou H, Li J. Paxlovid administration in elderly patient with COVID-19 caused by omicron BA.2.0: a case report. Medicine (Baltimore). 2022;101:e31361.
pubmed: 36397388
doi: 10.1097/MD.0000000000031361
Lu G, Zhang Y, Zhang H, Ai J, He L, Yuan X, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai omicron wave. Emerg Microbes Infect. 2022;11:2045–54.
pubmed: 35924388
pmcid: 9448390
doi: 10.1080/22221751.2022.2109517
Zhong W, Yang X, Jiang X, Duan Z, Wang W, Sun Z, et al. Factors associated with prolonged viral shedding in older patients infected with omicron BA.2.2. Front. Public Health. 2022;10:1087800.
Gentry CA, Nguyen P, Thind SK, Kurdgelashvili G, Williams RJ. Characteristics and outcomes of US veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Inf Secur. 2023;86:248–55.
Bihan K, Lipszyc L, Lemaitre F, Dautriche A, Fedrizzi S, Atzenhoffer M, et al. Nirmatrelvir/ritonavir (Paxlovid(R)): French pharmacovigilance survey 2022. Therapie. 2023;78:531-47.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022;54:516–23.
pubmed: 35118917
pmcid: 8820829
doi: 10.1080/07853890.2022.2034936
Ganipisetti VM, Bollimunta P, Maringanti S. Paxlovid-Induced Symptomatic Bradycardia and Syncope. Cureus. 2023;15:e33831.
pubmed: 36655157
pmcid: 9842109
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76:e342–9.
pubmed: 35653428
doi: 10.1093/cid/ciac443